Name: Latest research reports of Alembic Pharmaceuticals Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Alembic Pharmaceuticals Ltd.
Rating: 3
Author: Motilal Oswal

Exports drive earnings; weak show in DF segment

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma (ALPM) delivered better-than-expected 4QFY24 earnings,
led by better gross margin and improved off-take in the API segment. After
two consecutive years of weak financial performance, ALPM ended FY24
with 10%/14%/43% YoY growth in sales/EBIDTA/PAT to INR62b/INR9.3b/
INR6b.